Niemeijer et al. analyzed immuno-PET in patients with non-small cell lung cancer (NSCLC) and verified that tumor PD-L1 and PD-1 expression was accurately determined non-invasively using [18F]BMS-986192 and [89Zr]Nivolumab PET/CT, respectively [60]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.